Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT

NCT04624828 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Oligorecurrent and Oligoprogressive Prostate Cancer Patients

Interventions

PROCEDURE: Radiotherapy
DRUG: androgen deprivation therapy (ADT)
BIOLOGICAL: immune evaluation

Sponsor

Istituto Clinico Humanitas

Collaborators

[object Object]